EB613 Set to Become First Once-Daily Oral Tablet for Osteoporosis as Entera Bio Advances to Phase 3

Entera Bio receives positive FDA feedback on its pivotal Phase 3 trial design for EB613, the potential first once-daily oral tablet to stimulate bone formation in postmenopausal women with osteoporosis.